Oral nirmatrelvir-ritonavir for COVID-19 in higher risk outpatients
et al., New England Journal of Medicine, PANORAMIC, Sep 2025
PANORAMIC shows that paxlovid did not reduce hospitalization or death, adjusted OR 1.18, 95% Bayesian credible interval [0.55-2.62].
Ony minimal results are currently available in the abstract for a hidden paper.
The trial result was posted on the University of Cambridge Apollo repository on 9/10/2025 but has since been deleted. Neither NEJM nor the trial team has responded (other than by deleting the record). The accepted paper file is dated June, and the database record shows NEJM acceptance 9/9/2025 and publication 9/12/2025. Recruitment ended March 2024.
Standard of Care (SOC) for COVID-19 in the study country,
the United Kingdom, is very poor with very low average efficacy for approved treatments1.
The United Kingdom focused on expensive high-profit treatments, approving only one low-cost early treatment, which required a prescription and had limited adoption. The high-cost prescription treatment strategy reduces the probability of early treatment due to access and cost barriers, and eliminates complementary and synergistic benefits seen with many low-cost treatments.
|
risk of death/hospitalization, 17.9% higher, RR 1.18, p = 0.69, treatment 14 of 1,698 (0.8%), control 11 of 1,673 (0.7%), odds ratio converted to relative risk, day 28.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Richards et al., 12 Sep 2025, Randomized Controlled Trial, United Kingdom, peer-reviewed, 1 author, study period 12 April, 2022 - 28 March, 2024, PANORAMIC trial.
